Oncolytics Biotech Inc.
ONCY
$0.89
$0.011.40%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 119.31% | 3.06% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 143.65% | -15.43% | |||
| Operating Income | -143.65% | 15.43% | |||
| Income Before Tax | -142.08% | 5.69% | |||
| Income Tax Expenses | -398.05% | -- | |||
| Earnings from Continuing Operations | -134.63% | 4.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -134.63% | 4.37% | |||
| EBIT | -143.65% | 15.43% | |||
| EBITDA | -144.30% | 15.49% | |||
| EPS Basic | -110.61% | 11.07% | |||
| Normalized Basic EPS | -117.22% | 12.21% | |||
| EPS Diluted | -110.61% | 11.07% | |||
| Normalized Diluted EPS | -117.22% | 12.21% | |||
| Average Basic Shares Outstanding | 11.34% | 7.52% | |||
| Average Diluted Shares Outstanding | 11.34% | 7.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||